Kinoshita Y, Ishimura N, Ishihara S (2018) Advantages and disadvantages of long-term proton pump inhibitor Use. J Neurogastroenterol Motil 24:182–196. https://doi.org/10.5056/jnm18001

Article  PubMed  PubMed Central  Google Scholar 

Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953. https://doi.org/10.1001/jama.296.24.2947

Article  CAS  PubMed  Google Scholar 

Bavishi C, Dupont HL (2011) Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 34:1269–1281. https://doi.org/10.1111/j.1365-2036.2011.04874.x

Article  CAS  PubMed  Google Scholar 

Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, Francis N, Lyons RA, Dunstan F (2013) Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol 108:1094–1100. https://doi.org/10.1038/ajg.2013.30

Article  PubMed  Google Scholar 

Xu HB, Wang HD, Li CH, Ye S, Dong MS, Xia QJ, Zhang AQ, Pan K, Ge XL, Dong JH (2015) Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res 14:7490–7501. https://doi.org/10.4238/2015.July.3.25

Article  CAS  PubMed  Google Scholar 

Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ (2007) Clostridium difficile–associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 45:1543–1549. https://doi.org/10.1086/523582

Article  PubMed  Google Scholar 

Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA (2015) Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE 10:e0128004. https://doi.org/10.1371/journal.pone.0128004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK (2018) Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 67:28–35. https://doi.org/10.1136/gutjnl-2017-314605

Article  CAS  PubMed  Google Scholar 

Freedberg DE, Kim LS, Yang YX (2017) The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 152:706–715. https://doi.org/10.1053/j.gastro.2017.01.031

Article  CAS  PubMed  Google Scholar 

Seo SI, Park CH, You SC, Kim JY, Lee KJ, Kim J, Kim Y, Yoo JJ, Seo WW, Lee HS, Shin WG (2021) Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut 70:2066–2075. https://doi.org/10.1136/gutjnl-2020-323845

Article  PubMed  Google Scholar 

Shin GY, Park JM, Hong J, Cho YK, Yim HW, Choi MG (2021) Use of proton pump inhibitors vs histamine 2 receptor antagonists for the risk of gastric cancer: population-based cohort study. Am J Gastroenterol 116:1211–1219. https://doi.org/10.14309/ajg.0000000000001167

Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH, Quesenberry CP, Corley DA (2020) Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol 115:706–715. https://doi.org/10.14309/ajg.0000000000000591

Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L (2022) Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut 71:16–24. https://doi.org/10.1136/gutjnl-2021-325097

Article  CAS  PubMed  Google Scholar 

Gao H, Li L, Geng K, Teng C, Chen Y, Chu F, Zhao Y (2022) Use of proton pump inhibitors for the risk of gastric cancer. Medicine (Baltimore) 101:e32228. https://doi.org/10.1097/MD.0000000000032228

Article  CAS  PubMed  Google Scholar 

Piovani D, Tsantes AG, Schunemann HJ, Bonovas S (2023) Meta-analysis: use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther 57:653–665. https://doi.org/10.1111/apt.17360

Article  CAS  PubMed  Google Scholar 

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–789. https://doi.org/10.1056/NEJMoa001999

Article  CAS  PubMed  Google Scholar 

Haastrup PF, Jarbol DE, Thompson W, Hansen JM, Sondergaard J, Rasmussen S (2021) When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 8. https://doi.org/10.1136/bmjgast-2020-000563

Pottegard A, Broe A, Hallas J, de Muckadell OB, Lassen AT, Lodrup AB (2016) Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol 9:671–678. https://doi.org/10.1177/1756283X16650156

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee J, Lee JS, Park SH, Shin SA, Kim K (2017) Cohort profile: the national health insurance service-national sample cohort (NHIS-NSC). South Korea Int J Epidemiol 46:e15. https://doi.org/10.1093/ije/dyv319

Article  PubMed  Google Scholar 

Seong SC, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, Do CH, Song JS, Hyon Bang J, Ha S, Lee EJ, Ae Shin S (2017) Data resource profile: the national health information database of the national health insurance service in South Korea. Int J Epidemiol 46:799–800. https://doi.org/10.1093/ije/dyw253

Article  Google Scholar 

Song SO, Jung CH, Song YD, Park CY, Kwon HS, Cha BS, Park JY, Lee KU, Ko KS, Lee BW (2014) Background and data configuration process of a nationwide population-based study using the korean national health insurance system. Diabetes Metab J 38:395–403. https://doi.org/10.4093/dmj.2014.38.5.395

Article  PubMed  PubMed Central  Google Scholar 

Choi IJ, Kim YI, Park B (2018) Helicobacter pylori and prevention of gastric cancer. N Engl J Med 378:2244–2245. https://doi.org/10.1056/NEJMc1805129

Article  PubMed  Google Scholar 

Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, Meheus F, Verhoeven RHA, Vignat J, Laversanne M, Ferlay J, Soerjomataram I (2022) The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalMedicine 47:101404. https://doi.org/10.1016/j.eclinm.2022.101404

Article  PubMed  PubMed Central  Google Scholar 

Mukaisho K, Nakayama T, Hagiwara T, Hattori T, Sugihara H (2015) Two distinct etiologies of gastric cardia adenocarcinoma: interactions among pH, Helicobacter pylori, and bile acids. Front Microbiol 6:412. https://doi.org/10.3389/fmicb.2015.00412

Article  PubMed  PubMed Central  Google Scholar 

Dacha S, Razvi M, Massaad J, Cai Q, Wehbi M (2015) Hypergastrinemia Gastroenterol Rep (Oxf) 3:201–208. https://doi.org/10.1093/gastro/gov004

Article  PubMed  Google Scholar 

Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ (2015) Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 42:649–663. https://doi.org/10.1111/apt.13324

Article  CAS  PubMed  Google Scholar 

Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A (2016) Proton pump inhibitors affect the gut microbiome. Gut 65:740–748. https://doi.org/10.1136/gutjnl-2015-310376

Article  CAS  PubMed  Google Scholar 

Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK (2014) Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2:42. https://doi.org/10.1186/2049-2618-2-42

Article  PubMed  PubMed Central  Google Scholar 

Wroblewski LE, Peek RM Jr, Coburn LA (2016) The role of the microbiome in gastrointestinal cancer. Gastroenterol Clin North Am 45:543–556. https://doi.org/10.1016/j.gtc.2016.04.010

Article  PubMed  PubMed Central  Google Scholar 

Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG (1996) Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334:1018–1022. https://doi.org/10.1056/NEJM199604183341603

Article  CAS  PubMed  Google Scholar 

Li Z, Wu C, Li L, Wang Z, Xie H, He X, Feng J (2017) Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: a meta-analysis. Saudi J Gastroenterol 23:222–228. https://doi.org/10.4103/sjg.SJG_573_16

Article  PubMed  PubMed Central  Google Scholar 

Park YH, Kim N (2015) Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 20:25–40. https://doi.org/10.15430/JCP.2015.20.1.25

Abrahami D, Azoulay L (2022) Response by Abrahami et al to letter regarding article ‘Proton pump inhibitors and risk of colorectal cancer.’ Gut 71:1690–1691. https://doi.org/10.1136/gutjnl-2021-326544

Article  PubMed  Google Scholar 

Jung KW, Won YJ, Kong HJ, Lee ES (2019) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 51:417–430. https://doi.org/10.4143/crt.2019.138

Article  PubMed  PubMed Central  Google Scholar 

Sekiguchi M, Oda I, Matsuda T, Saito Y (2022) Epidemiological trends and future perspectives of gastric cancer in Eastern Asia. Digestion 103:22–28. https://doi.org/10.1159/000518483

Article  CAS  PubMed  Google Scholar 

Kanno T, Moayyedi P (2019) Proton pump inhibitors in the elderly, balancing risk and benefit: an age-old problem. Curr Gastroenterol Rep 21:65.